ADOCIA announces availability of 2021 Universal Registration Documents

Lyon, France – (BUSINESS WIRE) – Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, is the 2021 Universal Registration Document of Autoritédes. Announced the submission of. Marche Financier (AMF) on April 21, 2022.

This document is available electronically on our website ( and the AMF website ( Copies are also available at the company’s registration office, 115, Avenue La Casagne, 69003 Lyon.

The Universal Registration Document includes, among other things, the 2021 Annual Financial Report, which includes the Management Report and the 2021 Corporate Governance Report.

About Adoshia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions primarily in the areas of metabolic disorders such as diabetes and obesity. The company has a large portfolio of candidate drugs from three proprietary technology platforms.

1) Bio chaperone®, A technique for developing new generations of insulin and combinations that associate insulin with other hormone families. 2) AdOral®Oral peptide delivery technology; 3) TeenShell®An immunoprotective biomaterial for cell transplantation, with initial application to pancreatic cells for patients suffering from so-called “unstable” diabetes.

Adocia has more than 25 patent families and is ranked And 7th In the SME INPI ranking on the number of patents filed in 2019 and 2020.

Based in Lyon, the company has approximately 125 employees. Adocia is a company listed on the Euronext marketTM Paris (Euronext: ADOC; ISIN: FR0011184241).


This press release contains forward-looking statements about Adocia and its business. Adocia believes that these forward-looking statements are based on reasonable assumptions. However, we cannot guarantee the achievement of the forecasts shown in these forward-looking statements. These forecasts are subject to risks, including those described in Adocia’s Universal Registration Document filed with the Autorité des marchés financial institution on April 21, 2022. Uncertainty inherent in Adocia’s website (, especially R & D, future clinical data, analysis, and economic conditions, financial markets, and market changes in which Adocia resides.

The forward-looking statements contained in this press release are also exposed to risks that Adocia does not know about or that Adocia does not consider materiality at this time. The realization of all or part of these risks may result in Adocia’s actual results, financial position, performance or performance that differ materially from those expressed in these Declarations. .. This press release and the information contained therein do not constitute an offer to sell or subscribe to Adocia shares in any country, or to solicit purchase or subscription orders.

contact address

Gerald Surah

[email protected]
+33 4 72 610 610

Ulysses Communication
Relationship between Adocia Press and Investors

Pierre Louis Germain
[email protected] / + 33 (0) 6 64 79 97 51

Arisak’s Margopeek Country
[email protected] / +33 (0) 7 86 16 01 09

Bruno Arabian
[email protected] / +33 (0) 6 87 88 47 26